Compare OneSpan Inc (OSPN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs BIO-TECHNE Corp — how do they compare? OneSpan Inc trades at $15.21 (market cap $571.66M), while BIO-TECHNE Corp trades at $71.81 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 19.5× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| OSPN | TECH | |
|---|---|---|
Market Cap | $571.66M | $11.16B |
Sector | Technology | Health |
52-Week High | $16.32 | $72.12 |
52-Week Low | $10.15 | $43.31 |
Enterprise Value | $529.87M | $11.24B |
Dividend Yield | 3.37% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $15.51, up 0.26% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and a low P/E of 8.57, indicating potential undervaluation. Recent earnings have consistently beaten expectations, and the company announced a $0.13 dividend for H1 2026. Analyst sentiment is positive with a 66.7% buy rating, though the consensus price target of $13.50 is below the current price.
The outlook for OSPN is cautiously optimistic, supported by solid fundamentals and positive earnings momentum. Key opportunities include attractive valuation and consistent profitability. Risks include negative net cash flow trends and competitive pressures in the cybersecurity sector. Investors should weigh the strong analyst buy sentiment against the below-consensus price target.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
